Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma MarPHMMF 69 EV-to-OCF is 20.32 as of Aug. 11, 2026, which is 94% above its 10-year median of 10.48. GuruFocus rates PHMMF with a GF Score™ of 69/100 and a GF Value™ of $92.19 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Pharma Mar ranks worse than 88.12% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Pharma Mar's Enterprise Value is $1,477.4 Mil.
Pharma Mar's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $72.7 Mil. Therefore, Pharma Mar's EV-to-OCF for today is 20.32.
The historical rank and industry rank for Pharma Mar's EV-to-OCF or its related term are showing as below:
PHMMF'
s EV-to-OCF Range Over the Past 10 Years
Min: -708.95 Med: 10.48 Max: 777.12
Current: 19.85
During the past 13 years, the highest EV-to-OCF of Pharma Mar was 777.12. The lowest was -708.95. And the median was 10.48.
PHMMF's EV-to-OCF is ranked worse than 88.12% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs PHMMF: 19.85
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharma Mar's share price for today is $87.579.
Pharma Mar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.505.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pharma Mar EV-to-OCF Related Terms
Pharma Mar EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Pharma Mar's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharma Mar's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Pharma Mar's EV-to-OCF falls into.
Pharma Mar's current Enterprise Value is $1,477.4 Mil.
Pharma Mar's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Mar (PHMMF) has a EV-to-OCF of 20.32 as of Aug. 11, 2026. This is 94% above median its historical median of 10.48. According to the industry distribution chart, Pharma Mar ranks #1239 out of 1406 companies in the Biotechnology industry, placing it in the top 88.1%.
Is Pharma Mar's EV-to-OCF too high?
Pharma Mar's current EV-to-OCF of 20.32 is 94% above median its 10-year median of 10.48. Based on the distribution chart, Pharma Mar ranks #1239 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharma Mar has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #1239 out of 1406 companies for EV-to-OCF. This places Pharma Mar in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Pharma Mar's current EV-to-OCF is 20.32, which is 94% above median its own 10-year median of 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $92.19, compared to a current price of $87.58 — trading 5% below its estimated fair value. The current EV-to-OCF is 20.32, which is 94% above median its 10-year median of 10.48. Pharma Mar's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current EV-to-OCF is 20.32 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $87.58 is trading 5% below its estimated GF Value™ of $92.19.
GuruFocus considers Pharma Mar to be Fairly Valued.
Key valuation signals for PHMMF:
EV-to-OCF: 20.32 (94% above median its 10-year median of 10.48)
GF Value™: $92.19 vs. price of $87.58 (5% below fair value)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
69GF Score
Get the complete analysis for PHMMF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
